-

MedinCell Secures €10.9 Million Non-Dilutive Financing

MONTPELLIER, France--(BUSINESS WIRE)--MedinCell (Paris:MEDCL):

€10.9 million loan to increase the Company's financial visibility

Loan taken out with Banque Populaire du Sud and BNP Paribas in the form of PGE

Annual results for the FY ended March 31, 2020 will be published on June 4, 2020, after market close. As a reminder, a dedicated videoconference will be held at this occasion on Thursday, June 4:

  • 6.30 pm CEST – Presentation and Q&A in French
  • 7.30 pm CEST – Presentation and Q&A in English
  • Link to connect (only via internet): invest.medincell.com/conference

"We have maintained all operations related to strategic research and development programs since the beginning of the Coronavirus crisis, but other activities have been delayed," said Jaime Arango, Chief Financial Officer of MedinCell.

"Thanks to our partner banks who quickly mobilized to grant us this loan, we will be able to gradually return to normal activity level and advance as quickly as possible our Covid-19 program, which aims to develop a preventive treatment against the virus (prophylaxis)."

"The second half of the year should be rich for MedinCell, with potential milestones for several products based on our BEPO® technology currently in clinical studies. "

The loan is structured as a PGE (State Guaranteed Loan) with an initial maturity of 12 months at a 0,25% rate and an option for up to 5 years extension.

Contacts

MedinCell
David Heuzé
Communication leader
david.heuze@medincell.com
+33 (0)6 83 25 21 86

NewCap
Louis-Victor Delouvrier
Relation investisseurs
medincell@newcap.eu
+33 (0)1 44 71 98 53

NewCap
Nicolas Merigeau
Relations médias
medincell@newcap.eu
+33 (0)1 44 71 94 98

MedinCell

BOURSE:MEDCL

Release Versions

Contacts

MedinCell
David Heuzé
Communication leader
david.heuze@medincell.com
+33 (0)6 83 25 21 86

NewCap
Louis-Victor Delouvrier
Relation investisseurs
medincell@newcap.eu
+33 (0)1 44 71 98 53

NewCap
Nicolas Merigeau
Relations médias
medincell@newcap.eu
+33 (0)1 44 71 94 98

More News From MedinCell

Medincell’s ISS ESG Corporate Rating Upgraded

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announces that ISS has upgraded the company’s ESG rating from C+ to B. Medincell is ranked within the first decile of the Pharmaceuticals & Biotechnology sector, benefits from ISS ESG Prime Status, and achieves a very high level of ESG disclosure transparency. This updated rating is...

Medincell - UZEDY®: Net Sales Increased from $117M in 2024 to $191M in 2025 (+63%)

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell’s (Paris:MEDCL) partner, Teva Pharmaceuticals, today shared the following information in connection with the publication of its Q4 and full‑year 2025 results: About UZEDY® 2025 net sales reached $191 million, including $55 million in the fourth quarter Teva’s initial 2026 net sales outlook is in the range of $250 - $280 million Medincell receives mid‑to high‑single-digit royalties on UZEDY® net sales and is eligible for up to $105...

Medincell: Half-year Liquidity Contract Statement

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Under the liquidity contract entrusted by Medincell (Paris:MEDCL) to Rothschild Martin Maurel, the following resources were included in the liquidity account at December 31, 2025: 980 shares 1 159 804 € Over the period from 01/07/2025 to 31/12/2025, a total of: Number of executions Number of shares Traded volume in EUR Buy side 13,642 1,007,509 25,098,637.27 Sell side 14,870 1,011,529 25,113,263.98 It should be noted that Medincell increase...
Back to Newsroom